Harvard tightens rules on industry payments to top professorsBMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c172 (Published 12 January 2010) Cite this as: BMJ 2010;340:c172
- Janice Hopkins Tanne
- 1New York
Harvard University has tightened its regulations for doctors and scientists who consult for drug companies and medical device makers.
Ties between prominent doctors and drug companies have been scrutinised lately, especially by Senator Chuck Grassley, an Iowa Republican.
About two dozen of Harvard’s highest flyers, those who sit on the boards of drug companies, are most affected. Under the rules, introduced on 1 January, they can earn no more than $5000 (£3100; €3440) per 10 hour day for service on the board of a drug or device company and may not accept company stock in payment.
The rules also apply to about 6000 doctors, researchers, institutional officers, and other employees at Partners HealthCare, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial